2. Academic Validation
  3. Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors

Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors

  • Eur J Med Chem. 2021 Feb 5:211:113095. doi: 10.1016/j.ejmech.2020.113095.
Leandro A Alves Avelar 1,  Christian Schrenk 1,  Melf Sönnichsen 1,  Alexandra Hamacher 1,  Finn K Hansen 2,  Julian Schliehe-Diecks 3,  Arndt Borkhardt 3,  Sanil Bhatia 4,  Matthias U Kassack 5,  Thomas Kurz 6
Affiliations

Affiliations

  • 1 Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, 40225, Düsseldorf, Germany.
  • 2 Pharmazeutisches Institut, Abteilung für Pharmazeutische und Zellbiologische Chemie, Universität Bonn, An der Immenburg 4, 53121, Bonn (Endenich), Germany.
  • 3 Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • 4 Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. Electronic address: sanil.bhatia@med.uni-duesseldorf.de.
  • 5 Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, 40225, Düsseldorf, Germany. Electronic address: matthias.kassack@hhu.de.
  • 6 Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, 40225, Düsseldorf, Germany. Electronic address: thomas.kurz@hhu.de.
PMID: 33360560 DOI: 10.1016/j.ejmech.2020.113095
Abstract

Targeting epigenetic dysregulation has emerged as a valuable therapeutic strategy in Cancer treatment. Especially epigenetic combination therapy of histone deacetylase inhibitors (HDACi) with established anti-cancer drugs has provided promising results in preclinical and clinical studies. The structural optimization of alkoxyamide-based class I/IIb inhibitors afforded improved analogs with potent efficacy in cisplatin-resistant head and neck carcinoma cells and bortezomib-resistant leukemia cells. The most promising HDACi showed a superior synergistic cytotoxic activity as compared to vorinostat and class I HDACi in combination with cisplatin, leading to a full reversal of the chemoresistant phenotype in head and neck Cancer cell lines, as well in combination with the Proteasome inhibitors (bortezomib and carfilzomib) in a panel of leukemic cell lines. Furthermore, the most valuable alkoxyamide-based HDACi exhibited strong ex vivo Anticancer efficacy against primary patient samples obtained from different therapy-resistant leukemic entities.

Keywords

Cancer resistance; Chemosensitizing effects; Class I; Class IIb inhibitors; HDAC isozyme Profile; Histone deacetylases; Leukemia; Solid cancer.

Figures
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验，部分功能也使用 Cookies 帮助我们更好地理解您的需求，为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问，请阅读我们的《隐私声明》。

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z